CJC-1295 wo DAC CJC-1295 wo DAC PRODUCT IMAGE
HPLC VERIFIED COA SUPPLIED ≥99.1% PURITY
— Growth

CJC-1295 wo DAC Growth Hormone Releasing Factor Analogue (no DAC)

For in vitro research use only. CJC-1295 wo DAC is not for human or veterinary consumption, diagnosis, treatment, or prevention of any condition.

CJC-1295 (without DAC) is a synthetic version of a signal molecule the brain naturally uses to trigger growth hormone release. Without the DAC (Drug Affinity Complex — a chemical attachment that makes some versions last much longer in the body), this compound produces a short, sharp pulse of growth hormone — more like the natural pattern the body uses.

CAS Number
863288-34-0
Molecular Formula
C₁₅₂H₂₅₂N₄₄O₄₂
HPLC Purity
99.1% (batch-verified)
Form
Lyophilised powder
Storage
2–8°C, desiccated, protected from light
Classification
Research reagent — in vitro use only

Research overview

CJC-1295 (without DAC) is a synthetic analogue of GHRH (Growth Hormone-Releasing Hormone — the natural signal the brain uses to tell the body to make growth hormone). Without the DAC (Drug Affinity Complex — a chemical attachment that extends the compound's lifespan in the body), this version produces a brief, concentrated pulse of growth hormone release rather than a prolonged one. This makes it more similar to the natural pattern of growth hormone secretion. Animal studies have measured how it affects levels of GH (growth hormone) and IGF-1 (a related signalling protein that responds to growth hormone). Researchers often study it alongside another compound called Ipamorelin in growth hormone secretion research. For research use only. Not for human or veterinary consumption.

Summary paraphrased from the peer-reviewed preclinical literature. Full citations will be available in the research library. For in vitro research use only.

Compound specifications

Common nameCJC-1295 wo DAC
Full nameGrowth Hormone Releasing Factor Analogue (no DAC)
CAS number863288-34-0
Molecular formulaC₁₅₂H₂₅₂N₄₄O₄₂
Molecular weight3367.8 g/mol
SequenceHAIBU-Y-D-Ala-DFA-LRKVLGQLSARKLLQDIMSR-NH2 (no DAC)
HPLC purity99.1% (batch-verified)
AppearanceWhite to off-white lyophilised powder
SolubilityBacteriostatic water, sterile saline
Storage (lyophilised)2–8°C, protected from light
Storage (reconstituted)2–8°C, up to 28 days
Supplied as10mg

Batch testing and certificate of analysis

Every batch of CJC-1295 wo DAC is third-party HPLC-tested prior to dispatch. A batch-specific certificate of analysis documenting HPLC purity, mass spectrometry confirmation, and appearance is supplied with every order.

Previous batch CoAs are archived in the CoA library. For batch-specific CoA requests prior to purchase, contact veloxpeps@gmail.com.

Frequently Asked Research-Use Questions

What purity is Velox Peptides CJC-1295 wo DAC?
CJC-1295 wo DAC is supplied at 99.1% HPLC-verified purity. A certificate of analysis is provided with every order. Every batch is third-party tested before dispatch.
How is CJC-1295 wo DAC supplied and reconstituted for research use?
CJC-1295 wo DAC is supplied as a lyophilised powder in sterile single-use vials. For in vitro research use, reconstitution is performed with bacteriostatic water. See the reconstitution calculator for volume calculations based on required concentration.
What is CJC-1295 wo DAC used for in preclinical research?
CJC-1295 wo DAC is studied in the peer-reviewed literature across the pathways described in the research overview above. Velox Peptides supplies CJC-1295 wo DAC strictly as a research reagent for in vitro use by qualified researchers. It is not a medicinal product and is not for human or veterinary consumption.
What is the CAS number for CJC-1295 wo DAC?
The CAS registry number for CJC-1295 wo DAC is 863288-34-0. This identifier is listed on every batch certificate of analysis supplied with orders.

For in vitro research use only. CJC-1295 wo DAC is supplied solely as a research reagent for qualified professionals conducting in vitro or animal-model studies. It is not a medicinal product within the meaning of the Human Medicines Regulations 2012. It has not been evaluated by the MHRA or FDA. It is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale.

Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.